Category: General News
Search News
Dissecting complex biological pathways with machine learning
19th July 2021
We spoke with Group Leader Dr Jun Wang and Postdoctoral Researcher Dr Anthony Anene from Barts Cancer Institute’s Centre for Cancer Genomics & Computational Biology about their most recent publication. Published in Patterns, the paper describes the development of a machine-learning tool called ACSNI that can be used to predict tissue-specific pathway components from large biological datasets.
Read more
Understanding centrosome amplification in cancer
12th July 2021
Dr Susana Godinho, Group Leader in the Centre for Cancer Cell & Molecular Biology at Barts Cancer Institute, Queen Mary University of London, has recently received a Cancer Research UK Discovery Programme Foundation Award. The award of approximately £1.4 million over 6 years will support a research project that will investigate the impact of centrosome amplification in cancer.
Read more
Immune cells assemble – boosting the effects of chemotherapy in pancreatic cancer
9th July 2021
A new study from Barts Cancer Institute, Queen Mary University of London, has demonstrated that immune cells can be stimulated to assemble into special structures within pancreatic cancer such that, at least in a pre-clinical model, researchers can demonstrate an improvement in the efficacy of chemotherapy.
Read more
Doctoral training programme secures future investment from MRC
8th July 2021
A partnership between Queen Mary University of London and the University of Southampton has successfully bid for 45 studentships from the Medical Research Council (MRC), part of UK Research and Innovation (UKRI).
Read more
Study identifies biomarker that could help to diagnose pancreatic cancer
29th June 2021
Researchers from Barts Cancer Institute, Queen Mary University of London, have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate pancreatic cancer from other non-cancerous conditions of the pancreas.
Read more
BCI researcher part of team shortlisted for Cancer Grand Challenges awards
23rd June 2021
Dr Benjamin Werner from Barts Cancer Institute, Queen Mary University of London, is part of an international team that has been selected to share its ideas on how to solve one of cancer’s toughest challenges.
Read more